Levi & Korsinsky has filed a proposed securities class action against Regenxbio Inc. on behalf of investors who allegedly suffered losses between Feb. 9, 2022 and Jan. 27, 2026. The complaint claims the company misled investors about the efficacy and safety profile of its RGX-111 gene therapy program, and the suit follows the FDA’s clinical hold after a CNS tumor was found in a trial participant, which sent the stock down about 18% in one day. Investors have until April 14, 2026 to seek appointment as lead plaintiff.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603021600PRIMZONEFULLFEED9664149) on March 02, 2026, and is solely responsible for the information contained therein.